Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20877651 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
Condition: Type 2 Idiopathic Macular Telangiectasia
Intervention: Drug: Intravitreal injection ranibizumab

Indicates status has not been verified in more than two years